Trial Profile

A Phase 1, Multicenter, Randomized, Controlled, Open-Label, Perioperative Study of AG-120 and AG-881 in Subjects With Recurrent, Non-Enhancing, IDH1 Mutant, Low Grade Glioma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ivosidenib (Primary) ; Vorasidenib (Primary)
Indications Astrocytoma; Glioma; Oligodendroglioma
Focus Biomarker; Pharmacodynamics
Acronyms Window
Sponsors Agios Pharmaceuticals

Most Recent Events

15 May 2025 Status changed from active, no longer recruiting to completed.
22 Feb 2024 Planned End Date changed from 1 May 2024 to 1 May 2025.
08 Jun 2021 Results assessing biological impact of D-2-hydroxyglutarate suppression on tumors and tumor immune microenvironment presented at the 57th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com